Identification of monocyte-like precursors of granulocytes in cancer as a mechanism for accumulation of PMN-MDSCs
Open accessThe DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Abstract
We have identified a precursor that differentiates into granulocytes in vitro and in vivo yet belongs to the monocytic lineage. We have termed these cells monocyte-like precursors of granulocytes (MLPGs). Under steady state conditions, MLPGs were absent in the spleen and barely detectable in the bone marrow (BM). In contrast, these cells significantly expanded in tumor-bearing mice and differentiated to polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs). Selective depletion of monocytic cells had no effect on the number of granulocytes in naive mice but decreased the population of PMN-MDSCs in tumor-bearing mice by 50%. The expansion of MLPGs was found to be controlled by the down-regulation of Rb1, but not IRF8, which is known to regulate the expansion of PMN-MDSCs from classic granulocyte precursors. In cancer patients, putative MLPGs were found within the population of CXCR1+CD15−CD14+HLA-DR−/lo monocytic cells. These findings describe a mechanism of abnormal myelopoiesis in cancer and suggest potential new approaches for selective targeting of MDSCs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures











Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“S100hi monocytes (CD14 +S100hiHLAlo), which showed high expression of alarmins S100A8/A9/A12, TLR4 signaling pathways and low expression of MHC-II genes, characteristic of an M-MDSC signature14, and showed higher expression of the M-MDSC gene signature15 compared with other monocyte subtypes (Fig. 2e and Extended Data Table 2).”
From Single-cell atlas of human liver and blood immune cells across fatty liver disease stages reveals distinct signatures linked to liver dysfunction and fibrogenesis (2025) · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“M-MDSCs have been shown to differentiate into immunosuppressive S100A9+ macrophages (which could be profibrotic) through persistent expression of S100A9 (ref. 15)”
From Single-cell atlas of human liver and blood immune cells across fatty liver disease stages reveals distinct signatures linked to liver dysfunction and fibrogenesis (2025) · cites this paper as [15]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Persistent expression of S100A9 in M-MDSC-derived macrophages was reported to regulate their suppressive activity via the transcription factor CEBPB15”
From Single-cell atlas of human liver and blood immune cells across fatty liver disease stages reveals distinct signatures linked to liver dysfunction and fibrogenesis (2025) · cites this paper as [15]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106 · cited 2×
“DESeq2 (Love et al., 2014)”
RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome
Li, B., & Dewey, C. N. (2011) · BMC Bioinformatics · doi:10.1186/1471-2105-12-323 · Cited by 22,179 · cited 1×
“2.12 software (Li and Dewey, 2011) against mm10 genome and gene-level read counts, and reads per kilobase of transcript per million mapped read values on gene level were estimated for ensemble transcriptome.”
InfluentialStatistical significance for genomewide studies
Storey, J. D., & Tibshirani, R. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1530509100 · Cited by 9,692 · cited 1×
“Expression level comparisons between two groups were done using two-sample significance analysis of microarrays (SAM; Zhang, 2007), and correction for multiple testing to estimate FDR was done as described (Storey and Tibshirani, 2003), with FDR <5% used as a significance threshold.”
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720 · cited 1×
“MDSCs are directly implicated in negatively impacting patient responses to cancer therapies (Diaz-Montero et al., 2009; Arihara et al., 2013; Chen et al., 2014; Kawano et al., 2015; Romano et al., 2015; Lee et al., 2016; Tada et al., 2016; Wang et al., 2016; Wang and Yang, 2016), including…”
BackgroundFerroptosis: A Regulated Cell Death Nexus Linking Metabolism, Redox Biology, and Disease
Stockwell, B. R., Friedmann Angeli, J. P., Bayir, H., Bush, A. I., Conrad, M., Dixon, S. J., Fulda, S., Gascón, S., Hatzios, S. K., Kagan, V. E., et al. (2017) · Cell · doi:10.1016/j.cell.2017.09.021 · Cited by 7,695 · cited 1×
“To better characterize CD11b+Ly6G−Ly6Cint cells, we used the CCR2 marker of mature monocytes and the SiglecF marker of eosinophils/neutrophils (Stockwell et al., 2017).”
MethodCoordinated regulation of myeloid cells by tumours
Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544 · cited 1×
“There is now ample evidence suggesting that the success of cancer immunotherapies and even more traditional methods of treatment, such as radiation and chemotherapy, heavily depend on myeloid cells in the tumor microenvironment (Coussens and Pollard, 2011; Galdiero et al., 2013).”
BackgroundSelf-citationMechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF
Wan, P. T. C., Garnett, M. J., Roe, S. M., Lee, S., Niculescu-Duvaz, D., Good, V. M., Project, C. G., Jones, C. M., Marshall, C. J., Springer, C. J., et al. (2004) · Cell · doi:10.1016/s0092-8674(04)00215-6 · Cited by 2,808 · cited 1×
“Data were aligned using bowtie2 (Wan et al., 2004) and RSEM v1.”
MethodRecommendations for myeloid-derived suppressor cell nomenclature and characterization standards
Bronte, V., Brandau, S., Chen, S.-H., Colombo, M. P., Frey, A. B., Greten, T. F., Mandruzzato, S., Murray, P. J., Ochoa, A., Ostrand-Rosenberg, S., et al. (2016) · Nature Communications · doi:10.1038/ncomms12150 · Cited by 2,751
Self-citationA clonogenic common myeloid progenitor that gives rise to all myeloid lineages
Akashi, K., Traver, D., Miyamoto, T., & Weissman, I. L. (2000) · Nature · doi:10.1038/35004599 · Cited by 2,617
Prostate cancer in a transgenic mouse.
Greenberg, N. M., DeMayo, F., Finegold, M. J., Medina, D., Tilley, W. D., Aspinall, J. O., Cunha, G. R., Donjacour, A. A., Matusik, R. J., & Rosen, J. M. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.8.3439 · Cited by 1,294 · cited 2×
“Mastio et al. Journal of Experimental Medicine 2158 Monocytic precursors of granulocytes in cancer https://doi.org/10.1084/jem.20181952 important role in the switch between monocytic and granulocytic differentiation (Holtschke et al., 1996;Wang et al., 2014).”
BackgroundMethodInfluential
Cited by
Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity
Veglia, F., Sanseviero, E., & Gabrilovich, D. I. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-020-00490-y · Cited by 1,940
Self-citationElevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19
Silvin, A., Chapuis, N., Dunsmore, G., Goubet, A.-G., Dubuisson, A., Derosa, L., Almire, C., Hénon, C., Kosmider, O., Droin, N., et al. (2020) · Cell · doi:10.1016/j.cell.2020.08.002 · Cited by 834
MDSC: Markers, development, states, and unaddressed complexity
Hegde, S., Leader, A. M., & Merad, M. (2021) · Immunity · doi:10.1016/j.immuni.2021.04.004 · Cited by 669
Myeloid-derived suppressor cells in cancer and cancer therapy
Lasser, S. A., Ozbay Kurt, F. G., Arkhypov, I., Utikal, J., & Umansky, V. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00846-y · Cited by 489
Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy
Wu, Y., Yi, M., Niu, M., Mei, Q., & Wu, K. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01657-y · Cited by 458
“Intriguingly, a recent study identified a new group of monocyte lineage precursors that differentiated into a substantial subset of PMN-MDSCs, and they were designated as monocyte-like precursors of granulocytes (MLPGs) [15].”
BackgroundLin, H., Liu, C., Hu, A., Zhang, D., Yang, H., & Mao, Y. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01544-7 · Cited by 392
Neutrophil phenotypes and functions in cancer: A consensus statement
Quail, D. F., Amulic, B., Aziz, M., Barnes, B. J., Eruslanov, E., Fridlender, Z. G., Goodridge, H. S., Granot, Z., Hidalgo, A., Huttenlocher, A., et al. (2022) · Journal of Experimental Medicine · doi:10.1084/jem.20220011 · Cited by 340
“…2021; Gershkovitz et al., 2018a; Gershkovitz et al., 2018b; Hirschhorn-Cymerman et al., 2020; Martinez Sanz et al., 2021; Martı́nez-Sanz et al., 2021; Matlung et al., 2018) and enhanced tumor cell clearance (Blaisdell et al., 2015; Eruslanov et al., 2014; Singhal et al., 2016), particularly in…”
BackgroundVeglia, F., Hashimoto, A., Dweep, H., Sanseviero, E., De Leo, A., Tcyganov, E., Kossenkov, A., Mulligan, C., Nam, B., Masters, G., et al. (2021) · Journal of Experimental Medicine · doi:10.1084/jem.20201803 · Cited by 308
Self-citationTherapeutic targeting of tumour myeloid cells
Barry, S. T., Gabrilovich, D. I., Sansom, O. J., Campbell, A. D., & Morton, J. P. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-022-00546-2 · Cited by 305
Self-citationAn IL-4 signalling axis in bone marrow drives pro-tumorigenic myelopoiesis
LaMarche, N. M., Hegde, S., Park, M. D., Maier, B. B., Troncoso, L., Le Berichel, J., Hamon, P., Belabed, M., Mattiuz, R., Hennequin, C., et al. (2024) · Nature · doi:10.1038/s41586-023-06797-9 · Cited by 197
“…LY6C − GMPs (LY6C − CD115 − ) with similar monocyte and granulocyte developmental potential, granulocyte progenitors (GPs; LY6C + CD115 − ), which are more biased towards the granulocyte lineage, and common monocyte progenitors (cMoPs; LY6C + CD115 + ) biased towards monocyte development 16,33,34 .”
CD300ld on neutrophils is required for tumour-driven immune suppression
Wang, C., Zheng, X., Zhang, J., Jiang, X., Wang, J., Li, Y., Li, X., Shen, G., Peng, J., Zheng, P., et al. (2023) · Nature · doi:10.1038/s41586-023-06511-9 · Cited by 181
Kwak, T., Wang, F., Deng, H., Condamine, T., Kumar, V., Perego, M., Kossenkov, A., Montaner, L. J., Xu, X., Xu, W., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108571 · Cited by 178
“A significant proportion of those genes (16%, 72 genes; 2.3-fold more than expected by chance; p = 2 × 10 −13 by Fisher’s exact test) were also different between M-MDSCs and Mons (Figure S1C).”
InfluentialSelf-citationMyeloid-Derived Suppressor Cells: A Propitious Road to Clinic
Grover, A., Sanseviero, E., Timosenko, E., & Gabrilovich, D. I. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0764 · Cited by 175
Self-citationMyeloid Cells in Glioblastoma Microenvironment
Leo, A. D., Ugolini, A., & Veglia, F. (2020) · Cells · doi:10.3390/cells10010018 · Cited by 168
Self-citationDeciphering the state of immune silence in fatal COVID-19 patients
Bost, P., De Sanctis, F., Canè, S., Ugel, S., Donadello, K., Castellucci, M., Eyal, D., Fiore, A., Anselmi, C., Barouni, R. M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21702-6 · Cited by 149
Hou, A., Hou, K., Huang, Q., Lei, Y., & Chen, W. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00783 · Cited by 145
“In cancer patients, it seemed that CXCR1+CD15−CD14+HLA-DR−/lowmonocytic cells are enriched for the population of monocyte-like precursors of granulocytes (29).”
BackgroundMyeloid-derived suppressor cells in hematological malignancies: friends or foes
Lv, M., Wang, K., & Huang, X. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0797-3 · Cited by 136
“as CXCR1CD15CD14HLA-DR [13] PD-L1+ CD11bCD33HLA-DR [14] MDSC in tumor microenvi-”
BackgroundReyes, M., Filbin, M. R., Bhattacharyya, R. P., Sonny, A., Mehta, A., Billman, K., Kays, K. R., Pinilla-Vera, M., Benson, M. E., MGH COVID-19 Collection & Processing Team, et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abe9599 · Cited by 115
Role of Tumor-Mediated Dendritic Cell Tolerization in Immune Evasion
DeVito, N. C., Plebanek, M. P., Theivanthiran, B., & Hanks, B. A. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02876 · Cited by 100
“In humans, M-MDSCs can be identified as CD11b+CD14+CD15−HLA-DRlo and PMN-MDSCs as CD11bCD14CD15HLA-DR (95).”
BackgroundInfluentialEpithelial and stromal co-evolution and complicity in pancreatic cancer
Hingorani, S. R. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-022-00530-w · Cited by 108
Notch-mediated lactate metabolism regulates MDSC development through the Hes1/MCT2/c-Jun axis
Zhao, J., Ye, Y., Gao, C.-C., Wang, L., Ren, K., Jiang, R., Hu, S., Liang, S.-Q., Bai, J., Liang, J.-L., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110451 · Cited by 108
Bo, M. D., Mattia, E. D., Baboçi, L., Mezzalira, S., Cecchin, E., Assaraf, Y. G., & Toffoli, G. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100702 · Cited by 101
Keeley, T. S., Costanzo-Garvey, D. L., & Cook, L. M. (2019) · Trends in cancer · doi:10.1016/j.trecan.2019.10.013 · Cited by 88
Zheng, Y., Wang, N., Wang, S., Zhang, J., Yang, B., & Wang, Z. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02696-z · Cited by 88
Smith, A. D., Lu, C., Payne, D., Paschall, A. V., Klement, J. D., Redd, P. S., Ibrahim, M. L., Yang, D., Han, Q., Liu, Z., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-3670 · Cited by 87
“MDSCs use variousmechanisms to suppress activation and function of T cells and NK cells to enable tumor immune escape (3).”
Bullock, K. K., & Richmond, A. J. (2021) · Cancers · doi:10.3390/cancers13246293 · Cited by 82
“A small population of M-MDSCs was initially postulated to be able to differentiate into G-MDSCs through downregulation of the retinoblastoma 1 (Rb1) gene [29]; however, this precursor population was later identified as monocyte-like precursors of granulocytes (MLPGs), and MLPGs contributed to up to 50% of the total G-…”
BackgroundMechanisms Driving Neutrophil-Induced T-cell Immunoparalysis in Ovarian Cancer
Emmons, T. R., Giridharan, T., Singel, K. L., Khan, A. N. H., Ricciuti, J., Howard, K., Toro, S. L. S.-D., Debreceni, I. L., Aarts, C. E. M., Brouwer, M. C., et al. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0922 · Cited by 80
“Polymorphonuclear (PMN)-MDSC result from disordered granulopoiesis (6) and are characterized by the ability to suppress Tcell activation.”
BackgroundTcyganov, E. N., Hanabuchi, S., Hashimoto, A., Campbell, D. G., Kar, G., Slidel, T. W. F., Cayatte, C., Landry, A. L., Pilataxi, F., Hayes, S., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci145971 · Cited by 80
“Although MDSC and their classical counterparts - neutrophils (PMN) and monocytes (MON) - share many phenotypic and morphological characteristics, they have distinct transcriptomic and proteomic profiles, metabolism, biochemical features as well as functions(1, 6-10).”
BackgroundSelf-citationCancer immune exclusion: breaking the barricade for a successful immunotherapy
Bruni, S., Mercogliano, M. F., Mauro, F. L., Russo, R. I. C., & Schillaci, R. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1135456 · Cited by 79
Tumors exploit CXCR4 hi CD62L lo aged neutrophils to facilitate metastatic spread
Peng, Z., Liu, C., Victor, A. R., Cao, D., Veiras, L. C., Bernstein, E. A., Khan, Z., Giani, J. F., Cui, X., Bernstein, K. E., et al. (2021) · OncoImmunology · doi:10.1080/2162402x.2020.1870811 · Cited by 73
IRF8: Mechanism of Action and Health Implications
Moorman, H. R., Reategui-Almonacid, Y., Poschel, D. B., & Liu, K. (2022) · Cells · doi:10.3390/cells11172630 · Cited by 69
Brandquist, N. D., & Kielian, T. (2025) · npj Biofilms and Microbiomes · doi:10.1038/s41522-025-00782-y · Cited by 63
“In tumor bearing mice, monocytic myeloid-derived suppressor cells (M-MDSCs) were found to exhibit plasticity 221 , similar to that observed in S. aureus PJI.”
Wang, S., Zhao, X., Wu, S., Cui, D., & Xu, Z. (2023) · Biomarker Research · doi:10.1186/s40364-023-00475-8 · Cited by 62
“According to current publications, precursor cells that differentiate into PMNMDSCs can also emanate from the monocyte lineage and are termed monocyte-like precursors of granulocytes (MLPGs) [18].”
BackgroundZhang, K., Zakeri, A., Alban, T. J., Dong, J., Ta, H. M., Zalavadia, A. H., Branicky, A., Zhao, H., Jurić, I., Husic, H., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2023.113661 · Cited by 62
“Because a significant portion of tumor-associated PMN-MDSCs may originate from monocytic progenitors with phenotypic resemblance of M-MDSCs, 32,64,69,70 we postulate that VISTA and ARG1 on total MDSC populations may be more relevant to prognosis.”
BackgroundThe heterogeneity of neutrophils in cancer and its implication for therapeutic targeting
Eruslanov, E. B., Nefedova, Y., & Gabrilovich, D. I. (2025) · Nature Immunology · doi:10.1038/s41590-024-02029-y · Cited by 63
“…− CD117 + precursor cells in tumor-bearing mice and CD15 − CD14 + HLADR neg–lo CXCR1 + cells in patients with cancer differentiated into PMN-MDSCs 41 , suggesting that neutrophil progenitor cells may differentiate to PMN-MDSCs through a differentiation path distinct from that used for…”
Self-citationCrosstalk Between Staphylococcus aureus and Innate Immunity: Focus on Immunometabolism
Horn, C. M., & Kielian, T. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.621750 · Cited by 47
Colligan, S. H., Amitrano, A. M., Zollo, R. A., Peresie, J., Kramer, E. D., Morreale, B. G., Barbi, J. J., Singh, P. K., Yu, H., Wang, J., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci158661 · Cited by 56
Self-citationIkeda, N., Kubota, H., Suzuki, R., Morita, M., Yoshimura, A., Osada, Y., Kishida, K., Kitamura, D., Iwata, A., Yotsumoto, S., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112165 · Cited by 55
Hashimoto, A., Fukumoto, T., Zhang, R., & Gabrilovich, D. I. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02588-7 · Cited by 54
Self-citationTumor associated macrophage in HPV+ tumors: Between immunosuppression and inflammation
Gorvel, L., & Olive, D. (2022) · Seminars in Immunology · doi:10.1016/j.smim.2022.101671 · Cited by 51
The recent progress of myeloid‐derived suppressor cell and its targeted therapies in cancers
Ren, R., Xiong, C., Ma, R., Wang, Y., Yue, T., Yu, J., & Shao, B. (2023) · MedComm · doi:10.1002/mco2.323 · Cited by 47
Single-cell atlas of the liver myeloid compartment before and after cure of chronic viral hepatitis
Cui, A., Li, B., Wallace, M. S., Gonye, A. L. K., Oetheimer, C., Patel, H., Tonnerre, P., Holmes, J. A., Lieb, D., Yao, B. S., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2023.02.040 · Cited by 46
Martin, O. P., Wallace, M. S., Oetheimer, C., Patel, H. B., Butler, E. C., Wong, L. P., Huang, P., Elbaz, J., Costentin, C., Salloum, S., et al. (2025) · Nature Immunology · doi:10.1038/s41590-025-02255-y · Cited by 45
“Persistent expression of S100A9 in M-MDSC-derived macrophages was reported to regulate their suppressive activity via the transcription factor CEBPB 15 and, in our data, 35% of MP_2 macrophages (which harbored a LAM or SAM signature) expressed S100A9 and CEBPB .”
InfluentialImmunosuppressive Tumor Microenvironment of Osteosarcoma
Taylor, A. M., Sheng, J., Ng, P. K. S., Harder, J. M., Kumar, P., Ahn, J. Y., Cao, Y., Dzis, A. M., Jillette, N., Goodspeed, A. E., et al. (2025) · Cancers · doi:10.3390/cancers17132117 · Cited by 45
“In addition, monocyte-like cells are a possible precursor of TAM and can contribute to the accumulation of MDSCs in cancer [47].”
Myeloid-driven mechanisms as barriers to antitumor CD8+ T cell activity
Colligan, S. H., Tzetzo, S. L., & Abrams, S. I. (2019) · Molecular Immunology · doi:10.1016/j.molimm.2019.12.012 · Cited by 44
Self-citationTargeting the myeloid microenvironment in neuroblastoma
Stip, M. C., Teeuwen, L., Dierselhuis, M. P., Leusen, J. H. W., & Krijgsman, D. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02913-9 · Cited by 43
“Furthermore, M-MDSCs can be differentiated from monocytes by lower or absent HLA class II expression and increased C-X-C motif chemokine receptor 1 (CXCR1) expression [25, 31].”
BackgroundThe Role of Myeloid-Derived Suppressor Cells (MDSCs) in Graft-versus-Host Disease (GVHD)
Demosthenous, C., Sakellari, I., Douka, V., Papayanni, P. G., Anagnostopoulos, Α., & Gavriilaki, E. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10102050 · Cited by 42
“Additional popula- tions have been described by several other groups, such as tumor-induced programmed death-ligand 1 (PD-L1)+ CD33+ CD11b+ HLA-DR− MDSCs, [29] CXCR1+ CD14+ CD15− HLA-DR−/low, [30], and secreted protein acidic and rich in cysteine (SPARC)-positive MDSCs [31].”
BackgroundCD66b+ monocytes represent a proinflammatory myeloid subpopulation in cancer
Horzum, U., Yöyen-Ermiş, D., Taşkıran, E. Z., Yılmaz, K. B., Hamaloğlu, E., Karakoç, D., & Esendağlı, G. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02656-y · Cited by 41
“Recently, monocyte-like precursors of granulocytes (MLPGs) were identified in human cancers that commit to PMN-MDSC, a similar phenomenon previously reported in the tumor-bearing mice [41, 42].”
BackgroundHarnessing myeloid cells in cancer
Park, S., Pylaeva, E., Bhuria, V., Gambardella, A. R., Schiavoni, G., Mougiakakos, D., Kim, S.-H., & Jabłońska, J. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02249-2 · Cited by 40
“Also, MDSC-like populations derived from hematopoietic progenitors are re-routed along with granulomonocytic differentiation [52, 53] by induction of unfolded protein response(UPR) and ER stress [54], apoptotic-stress response through C/ EBP-homologous protein (CHOP) [55], itaconate production [56]…”
Shi, H., Li, K., Ni, Y., Liang, X., & Zhao, X. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.707198 · Cited by 40
“A separate team also identified a monocytic lineage as the precursor of PMN-MDSCs and termed these cells monocyte-like precursors of granulocytes (Mastio et al., 2019).”
BackgroundModulation of T-cell function by myeloid-derived suppressor cells in hematological malignancies
Bhardwaj, V., & Ansell, S. M. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1129343 · Cited by 38
“A recent study also reported a monocytic lineage termed monocyte-like precursors of granulocytes (MLPGs) which differentiates into PMN-MDSCs (Mastio et al., 2019).”
BackgroundDing, Z., Aboelella, N. S., Bryan, L. J., Shi, H., & Zhou, G. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.594540 · Cited by 37
“It is worth noting that a subset of monocytes capable of giving rise to polymorphonuclear MDSCs (PMN-MDSCs), termed monocyte-like precursors of granulocytes (MLPGs), has been identified in tumor-bearing mice and patients with cancer (55).”
BackgroundDistinct Cell Adhesion Signature Defines Glioblastoma Myeloid-Derived Suppressor Cell Subsets
Bayık, D., Bartels, C. F., Lovrenert, K., Watson, D. C., Zhang, D., Kay, K. E., Lee, J., Lauko, A. J., Johnson, S., Lo, A., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-3840 · Cited by 36
“This is of particular importance as downregulation of IRF8 transcriptional profile is essential for the commitment of granulocyte progenitors that give rise to gMDSCs, whereas high IRF8 levels are required for the development of monocyte-DC progenitors that can differentiate into mMDSCs (35, 37, 38).”
Self-citationMyeloid-derived suppressor cell: A crucial player in autoimmune diseases
Xu, D., Li, C., Xu, Y., Huang, M., Cui, D., & Xie, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1021612 · Cited by 35
Groth, C., Arpinati, L., Shaul, M. E., Winkler, N., Diester, K., Gengenbacher, N., Weber, R., Arkhypov, I., Lasser, S., Petrova, V., et al. (2021) · Cancers · doi:10.3390/cancers13040726 · Cited by 34
“In addition, it has been recently reported that monocyte-like precursors of granulocytes were strongly expanded and differentiated to PMN-MDSC in tumor bearing mice that could explain an accumulation of this MDSC subset [38].”
BackgroundTumor microenvironment, histone modifications, and myeloid-derived suppressor cells
Tian, X., Wang, T., Shen, H., & Wang, S. (2023) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2023.08.002 · Cited by 34
Schrijver, I. T., Karakike, E., Théroude, C., Baumgärtner, P., Harari, A., Giamarellos‐Bourboulis, E. J., Calandra, T., & Roger, T. (2022) · Intensive Care Medicine Experimental · doi:10.1186/s40635-022-00431-0 · Cited by 33
“This might suggest that, under pathological conditions, these populations result from different hematopoietic drivers [33].”
BackgroundNauman, S., Basit, A. A., Munir, H., & Iqbal, M. S. (2023) · Project Management Journal · doi:10.1177/87569728231216897 · Cited by 30
“Some recent evidence shows that interpersonal trust is associated with megaproject success (Castro et al., 2023; Mastio et al., 2019), but no direct evidence is available to con fi rm whether inter-personal trust mediates the relationship between servant leadership and megaproject success.”
BackgroundAldrich, A. L., Horn, C. M., Heim, C. E., Korshoj, L. E., & Kielian, T. (2021) · The Journal of Immunology · doi:10.4049/jimmunol.2001042 · Cited by 28
“Examining the expression of genes that are associated with MDSCs versus mature PMNs allowed us to identity the largest granulocyte cluster I as G-MDSC-like based on increased expression of aconitate decarboxylase 1 (acod1), cd274 (Programmed death-ligand 1; PDL1), C-type lectin domain family 4 member E (clec4e), NF-κB…”
BackgroundCheng, G., Hardy, M., Topchyan, P., Zander, R., Volberding, P. J., Cui, W., & Kalyanaraman, B. (2021) · iScience · doi:10.1016/j.isci.2021.102673 · Cited by 28
Plackoska, V., Shaban, D., & Nijnik, A. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1041010 · Cited by 27
“Frontiers in Immunology 04 important precursor of tumor associate neutrophils (42).”
BackgroundMyeloid‐derived suppressor cells in the therapy of autoimmune diseases
Bekić, M., & Tomić, S. (2023) · European Journal of Immunology · doi:10.1002/eji.202250345 · Cited by 26
“An additional subset within M-MDSCs was identified as monocyte-like precursors of PMN-MDSCs (MLPG) in cancer patients and tumor-bearing mice models [18].”
BackgroundFu, S., Chen, G. T. Y., Wang, C., Yu, C., Chiang, C., & Hong, J. (2020) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2020.11.004 · Cited by 25
Self-citationBallesteros, I., & Hidalgo, A. (2025) · Cell · doi:10.1016/j.cell.2025.11.001 · Cited by 24
Ortega, M. C., Lebrón‐Galán, R., Machín-Díaz, I., Naughton, M., Pérez-Molina, I., García-Arocha, J., García‐Domínguez, J. M., Goicoechea-Briceño, H., Sol, V. V., Quintanero-Casero, V., et al. (2023) · Acta Neuropathologica · doi:10.1007/s00401-023-02593-x · Cited by 22
“CXCR1 is a chemokine receptor expressed on neutrophils and normally not associated with monocytes that has been described to be present in up to 20% of M-MDSCs, showing a reduced or absent immunosuppressive activity [25].”
BackgroundLiu, W., Shi, T., Lu, C., Che, K., Zhang, Z., Luo, Y., Hirschhorn, D., Wang, H., Liu, S., Wang, Y., et al. (2025) · Cell Research · doi:10.1038/s41422-025-01145-0 · Cited by 21
Myeloid-Derived Suppressor Cells: New Insights into the Pathogenesis and Therapy of MDS
Velegraki, M., Stiff, A. R., Papadaki, H. Α., & Li, Z. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11164908 · Cited by 21
“A population of monocytic lineage cells that are capable of differentiating into PMN-MDSCs has been identified, and this population was significantly expanded in the setting of cancer [11].”
BackgroundYu, J., Li, H., Zhang, Z., Lin, W., Wei, X., & Shao, B. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.647312 · Cited by 20
“Meanwhile, PMNMDSCs are defined as CD11bCD14CD33CD15 cells (10).”
BackgroundThe Role of Myeloid-Derived Suppressor Cells in Tumor Growth and Metastasis
Bayık, D., Lee, J., & Lathia, J. D. (2022) · Experientia supplementum · doi:10.1007/978-3-030-91311-3_7 · Cited by 20
Li, X., Liu, J., Xing, Z., Tang, J., Sun, H., Zhang, X., Lv, S., Chen, Z., Shi, M., Chen, M., et al. (2021) · Journal of Leukocyte Biology · doi:10.1002/jlb.3ma0821-029r · Cited by 19
Ponzo, M., Drufuca, L., Buracchi, C., Sindoni, M. M., Nucera, S., Bugarin, C., Bason, R., Rossetti, G., Bonnal, R. J. P., Meli, C., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-011768 · Cited by 18
Histone acetylation modulators in breast cancer
Yuan, X., & Rosen, J. M. (2025) · Breast Cancer Research · doi:10.1186/s13058-025-02006-9 · Cited by 16
“One study by Mas-tio et al. suggested that monocytic precursors can also differentiate into PMN-MDSCs [170].”
Emerging roles for myeloid immune cells in bone metastasis
Alsamraae, M., & Cook, L. M. (2021) · Cancer and Metastasis Reviews · doi:10.1007/s10555-021-09965-3 · Cited by 16
Savardekar, H., Allen, C., Jeon, H., Li, J., Quiroga, D. M., Schwarz, E. J., Wu, R. C. H., Zelinskas, S., Lapurga, G., Abreo, A., et al. (2023) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-22-0572 · Cited by 14
Myeloid Cell Reprogramming and Immune Suppression
Grover, A., Tcyganov, E. N., & Gabrilovich, D. I. (2025) · Annual Review of Physiology · doi:10.1146/annurev-physiol-050824-111031 · Cited by 13
Self-citationThe Role of Myeloid-Derived Suppressor Cells in Multiple Sclerosis and Its Animal Model
Jiang, Q., Duan, J., Kaer, L. V., & Yang, G. (2023) · Aging and Disease · doi:10.14336/ad.2023.0323-1 · Cited by 13
“Additionally, CXC-chemokine receptor 1, which is typically associated with neutrophil functions, is upregulated in human M-MDSCs, indicating its potential as a novel marker for M-MDSCs [16].”
BackgroundPatel, A. P., Oba, T., Kajihara, R., Yokoi, T., Abrams, S. I., & Ito, F. (2021) · The Journal of Immunology · doi:10.4049/jimmunol.2100281 · Cited by 13
Self-citationBertrand, B. P., Heim, C. E., Koepsell, S. A., & Kielian, T. (2023) · Journal of Leukocyte Biology · doi:10.1093/jleuko/qiad158 · Cited by 12
Tumor-derived GCSF Alters Tumor and Systemic Immune System Cell Subset Composition and Signaling
Matos, I., Barvalia, M., Chehal, M. K., Robertson, A. G., Kulić, I., Silva, J. A. F. D., Ranganathan, A., Short, A., Huang, Y., Long, E., et al. (2023) · Cancer Research Communications · doi:10.1158/2767-9764.crc-22-0278 · Cited by 11
“…are aimed at better distinguishing the subsets of MDSCs in tumors, blood, and organs (monocytic-MDSC, neutrophil vs. MDSC) using CyTOF and functional assays, and exploring the mechanistic balance between Neut and macrophages development, their progenitors and the impact of GCSF on thisprocess(53).”
Hypoxia-induced EGR1 remodels neutrophils to suppress antitumor immunity
Chang, T., Friedman, J., Clavijo, P. E., Robbins, Y. L., Craveiro, M., Huynh, A. P., Dar, M. S., Yang, X., Cao, Y., Sievers, C. M., et al. (2025) · Science Immunology · doi:10.1126/sciimmunol.adz2273 · Cited by 12
MDSCs and T cells in solid tumors and non-Hodgkin lymphomas: an immunosuppressive speech
Cioccarelli, C., & Molon, B. (2022) · Clinical & Experimental Immunology · doi:10.1093/cei/uxac025 · Cited by 11
Dabrafenib Alters MDSC Differentiation and Function by Activation of GCN2
Ciudad, M. T., Quevedo, R., Lamorte, S., Jin, R., Nzirorera, N., Koritzinsky, M., & McGaha, T. L. (2024) · Cancer Research Communications · doi:10.1158/2767-9764.crc-23-0376 · Cited by 11
“In tumors from dabrafenib-exposed mice, the percentage of m-MDSCs increased with a corresponding decrease in PMN-MDSCs (Fig.”
InfluentialCalabrò, A., Drommi, F., Migliore, G. S., Pezzino, G., Vento, G., Freni, J., Costa, G., Cavaliere, R., Bonaccorsi, I., Sionne, M., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25158470 · Cited by 11
“many . a 34 an ,36]. in a their [17]. it is CRC pts to assess whether, in CRC pts, the frequency of CD15+ monocytes and their ratio with lymphocytes might correlate with patients’ clinical outcomes and thus represent a novel prognostic/predictive marker.”
BackgroundInfluentialDai, Q., Peng, Y., He, P., & Wu, X. (2024) · Journal of drug targeting · doi:10.1080/1061186x.2024.2418344 · Cited by 9
“PMN-MDScs express cD11b and cD15, and M-MDScs exhibit monocytic features and express cD11b and cD14 in humans [172–174].”
Tumor-directed dysregulation of erythroid progenitors drives immunosuppressive myeloid cells
Mandula, J. K., & Rodríguez, P. C. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.04.017 · Cited by 9
Developmental pathways of myeloid-derived suppressor cells in neoplasia
Abrams, S. I. (2020) · Cellular Immunology · doi:10.1016/j.cellimm.2020.104261 · Cited by 9
“Additional investigations identified a novel granulocyte progenitor termed monocyte-like precursors of granulocytes (MLPGs) [73], also emerging as a potential descendant from GMPs.”
BackgroundSelf-citationThe crosstalk between lung cancer and the bone marrow niche fuels emergency myelopoiesis
Calderon-Espinosa, E., Ridder, K. D., Benoot, T., Jansen, Y. J. L., Vanhonacker, D., Heestermans, R., Becker, A. D., Riet, I. V., Decoster, L., & Goyvaerts, C. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1397469 · Cited by 8
Alhajahjeh, A. A., Stahl, M. F., Kim, T. K., Kewan, T. Z., Stempel, J. M., Zeidan, A. M., & Bewersdorf, J. P. (2025) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2025.2483855 · Cited by 7
“…the primary function of immune suppressor cells that undergo several functional profile changes resulting in the two major subtypes; however, research has shown that PMN-MDSCs can also arise from monocyte-like precursors of granulocytes (MLPGs) regulated by the retinoblastoma (Rb1) gene [38,73].”
Pan, J., Zhao, L., Du, H., Zhu, Y., Sun, X., Xu, Q., Cheng, H., Chen, H., & Sun, Y. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-013081 · Cited by 7
“46 Therefore, regulating the transition and differentiation of immature myeloid cells may be a promising strategy to eliminate MDSCs.”
Harnessing myeloid cell plasticity for cancer therapy
Sanseviero, E., Barry, S. T., & Gabrilovich, D. I. (2026) · Nature Cancer · doi:10.1038/s43018-026-01159-6 · Cited by 7
“…on microenvironmental cues 2–4 ; differentiation of lymphoid and monocytic progenitors and precursors into granulocytes under various pathological conditions 5,6 ; and, conversely, differentiation of neutrophil-committed progenitors or precursors into monocytes during emergency myelopoiesis 7,8 .”
InfluentialSelf-citationResearch Supporting a Pilot Study of Metronomic Dapsone during Glioblastoma Chemoirradiation
Kast, R. E. (2021) · Medical Sciences · doi:10.3390/medsci9010012 · Cited by 7
Chen, W., Ning, X., Liu, Y., Shen, T., Liu, M., Yin, H., Ding, Y., Zhou, J., Yin, R., Cai, L., et al. (2024) · Immunology · doi:10.1111/imm.13763 · Cited by 6
Self-citationYin, J., Wan, Y., Chen, G., Li, N., Liu, F., Luo, H., Li, Y., Li, S., & Jiang, Y. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1615753 · Cited by 5
Distinct Roles of Monocyte Subsets in Cancer
Cortez, M. A. S., Eilenberg, W. H., Neumayer, C., & Brostjan, C. (2025) · Cells · doi:10.3390/cells14241982 · Cited by 4
“Moreover, Mo-MDSCs promote tumor progression and facilitate metastasis by supporting tumor angiogenesis through the release of VEGF-α [27,66,70].”
Magalhães-Gama, F., Alves-Hanna, F. S., de Araújo, N. D., Barros, M. S., Silva, F. S., Catão, C. L. S., Moraes, J. S., Freitas, I. C., Tarragô, A. M., Malheiro, A., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1071188 · Cited by 4
Zhao, L., Ma, Y., Shu, Q., Sun, H., Lu, J., Gong, P., Meng, F., & Wan, F. (2025) · Pharmaceuticals · doi:10.3390/ph18040471 · Cited by 4
Skubitz, K. M., Domingo‐Musibay, E., Lindgren, B. R., & Cheng, E. Y. (2022) · Cancers · doi:10.3390/cancers14143419 · Cited by 4
“More recently, there is evidence that some cells that appear as monocytes in the circulation have the ability to transform into PMN-MDSCs [27].”
BackgroundShaban, D., Najm, N., Droin, L., & Nijnik, A. (2024) · Stem Cell Reviews and Reports · doi:10.1007/s12015-024-10782-8 · Cited by 4
“…in the discovery of new populations of myeloid precursor cells, as for example in neutrophil development [ 115–117 ], while other recent stud - ies indicated specific changes in the myeloid precursor cell hierarchies and functions in pathologic states, such as obe - sity and cancer [ 118 , 119 ].”
Refaat, Y., Rahman, Y. A., Saleh, M. F. M., Sayed, D. M., & Elzohri, M. H. (2022) · The Egyptian Journal of Haematology · doi:10.4103/ejh.ejh_37_22 · Cited by 3
Metadata
- Authors
- Mastio, J., Condamine, T., Dominguez, G., Kossenkov, A. V., Donthireddy, L., Veglia, F., Lin, C., Wang, F., Fu, S., Zhou, J., Viatour, P., Lavilla-Alonso, S., Polo, A. T., Tcyganov, E. N., Mulligan, C., Nam, B., Bennett, J., Masters, G., Guarino, M., Kumar, A., Nefedova, Y., Vonderheide, R. H., Languino, L. R., Abrams, S. I., & Gabrilovich, D. I.
- Affiliations
- The Wistar Institute (US)
- Sun Yat-sen University (CN)
- University of Pennsylvania (US)
- Asociación Demográfica Costarricense (CR)
- Christiana Care Health System (US)
- Thomas Jefferson University (US)
- Roswell Park Comprehensive Cancer Center (US)
- Corresponding author
- Gabrilovich, Dmitry I.
- ORCID
- Mastio, Jérôme
- Condamine, Thomas
- Dominguez, George
- Kossenkov, Andrew V.
- Donthireddy, Laxminarasimha
- Veglia, Filippo
- Lin, Cindy
- Wang, Fang
- Fu, Shuyu
- Zhou, Jie
- Viatour, Patrick
- Tcyganov, Evgenii N.
- Mulligan, Charles
- Nam, Brian
- Bennett, Joseph
- Masters, Gregory
- Kumar, Amit
- Nefedova, Yulia
- Vonderheide, Robert H.
- Languino, Lucia R.
- Abrams, Scott I.
- Gabrilovich, Dmitry I.
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2019-06-25
- Volume
- 216
- Issue
- 9
- Pages
- 2150-2169
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC6719429
- OpenAlex
- W2954317599
- Cited by
- 115
- References
- 52
- Citations by year
- 2026: 5 · 2025: 17 · 2024: 12 · 2023: 22 · 2022: 22 · 2021: 23 · 2020: 10 · 2019: 4
- FWCI
- 5.88
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Experimental Medicine (publishedVersion, cc-by-nc-sa)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- The Medicine Forum (submittedVersion, cc-by-nc-sa)
- Funders
- National Institutes of Health (CA084488, CA140043)
- Wistar Institute Animal and Bioinformatics (P30 CA010815)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Keywords
- polymorphonuclear myeloid-derived suppressor cells, RB1, IRF8, monocytic lineage, granulocytic differentiation, MDSC depletion, tumor immunosuppression
- MeSH terms
- Myeloid-Derived Suppressor Cells, Adult, Aged, Animals, Cell Differentiation, Female, Humans, Male, Mice, Inbred C57BL, Middle Aged, Monocytes, Neoplasms, Neutrophils, Mice, Retinoblastoma Binding Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.